CMVLF Stock - Cellectis S.A.
Unlock GoAI Insights for CMVLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.51M | $755,000 | $19.17M | $73.95M | $73.95M |
| Gross Profit | $41.51M | $18,000 | $17.40M | $37.67M | $37.67M |
| Gross Margin | 100.0% | 2.4% | 90.8% | 50.9% | 50.9% |
| Operating Income | $-59,554,000 | $-108,857,350 | $-89,666,000 | $-85,437,000 | $-85,437,000 |
| Net Income | $-36,761,000 | $-103,173,851 | $-106,139,000 | $-81,074,000 | $-81,074,000 |
| Net Margin | -88.6% | -13665.4% | -553.6% | -109.6% | -109.6% |
| EPS | $-0.41 | $-1.77 | $-2.33 | $-1.81 | $-1.91 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Visit WebsiteEarnings History & Surprises
CMVLFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.23 | $0.01 | +102.5% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-0.22 | $-0.24 | -5.7% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.15 | $-0.18 | -18.1% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.18 | $0.06 | +132.9% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $-0.24 | $-0.23 | +3.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.28 | $-0.28 | -0.8% | ✗ MISS |
Q2 2024 | May 28, 2024 | $-0.20 | $0.05 | +127.5% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $-0.29 | $-0.61 | -111.6% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.41 | $-0.31 | +23.8% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.44 | $-0.19 | +56.1% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.48 | $-0.58 | -20.6% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-0.81 | $-0.58 | +28.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.54 | $-0.63 | -16.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.68 | $-0.42 | +38.2% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.64 | $-0.62 | +3.1% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-1.10 | $-0.48 | +56.4% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.55 | $-0.71 | -29.1% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.60 | $-0.73 | -21.7% | ✗ MISS |
Q2 2021 | May 6, 2021 | — | $-0.28 | — | — |
Latest News
Frequently Asked Questions about CMVLF
What is CMVLF's current stock price?
What is the analyst price target for CMVLF?
What sector is Cellectis S.A. in?
What is CMVLF's market cap?
Does CMVLF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CMVLF for comparison